Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease

Current Opinion in Neurobiology

Volumn 17, Issue 3, 2007, Pages 331-337

  Dodson, Mark W ^a,b   Guo, Ming ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DJ 1 PROTEIN; PARKIN; PINK1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; REVIEW;

ANIMALS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIA; ONCOGENE PROTEINS; PARKINSON DISEASE; PROTEIN KINASES; UBIQUITIN-PROTEIN LIGASES;

EID: 34249937901     PISSN: 09594388     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.conb.2007.04.010     Document Type: Review

References (54)

1. Wood-Kaczmar A., Gandhi S., and Wood N.W. Understanding the molecular causes of Parkinson's disease. Trends Mol Med 12 (2006) 521-528
2. Greenamyre J.T., and Hastings T.G. Parkinson's - divergent causes, convergent mechanisms. Science 304 (2004) 1120-1122
3. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K., et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25 (2000) 302-305
4. Kahle P.J., and Haass C. How does parkin ligate ubiquitin to Parkinson's disease?. EMBO Rep 5 (2004) 681-685
5. Ko H.S., von Coelln R., Sriram S.R., Kim S.W., Chung K.K., Pletnikova O., Troncoso J., Johnson B., Saffary R., Goh E.L., et al. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci 25 (2005) 7968-7978. Although several Parkin substrates were identified in vitro, this study demonstrates the accumulation of only one, the aminoacyl-tRNA synthetase cofactor p38 protein, in parkin knockout mice.
6. Ko H.S., Kim S.W., Sriram S.R., Dawson V.L., and Dawson T.M. Identification of far upstream element-binding protein-1 as an authentic Parkin substrate. J Biol Chem 281 (2006) 16193-16196
7. Matsuda N., Kitami T., Suzuki T., Mizuno Y., Hattori N., and Tanaka K. Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in vitro. J Biol Chem 281 (2006) 3204-3209
8. Hampe C., Ardila-Osorio H., Fournier M., Brice A., and Corti O. Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum Mol Genet 15 (2006) 2059-2075
9. Doss-Pepe E.W., Chen L., and Madura K. α-Synuclein and parkin contribute to the assembly of ubiquitin lysine 63-linked multiubiquitin chains. J Biol Chem 280 (2005) 16619-16624
10. Lim K.L., Chew K.C., Tan J.M., Wang C., Chung K.K., Zhang Y., Tanaka Y., Smith W., Engelender S., Ross C.A., et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci 25 (2005) 2002-2009
11. Mukhopadhyay D., and Riezman H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 315 (2007) 201-205
12. Fallon L., Belanger C.M., Corera A.T., Kontogiannea M., Regan-Klapisz E., Moreau F., Voortman J., Haber M., Rouleau G., Thorarinsdottir T., et al. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat Cell Biol 8 (2006) 834-842. The authors report that following EGF stimulation, Parkin physically interacts with and ubiquitinates Eps15, an adaptor involved in EGFR endocytosis. Parkin-deficient cells exhibit increased EGFR endocytosis and decreased activation of the downstream EGFR target Akt, suggesting that Parkin-mediated ubiquitination of Eps15 inhibits EGFR internalization and thus maintains Akt signaling. This work provides significant mechanistic insight into Parkin function in a non-degradative context.
13. Pesah Y., Pham T., Burgess H., Middlebrooks B., Verstreken P., Zhou Y., Harding M., Bellen H., and Mardon G. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 131 (2004) 2183-2194
14. Greene J.C., Whitworth A.J., Kuo I., Andrews L.A., Feany M.B., and Pallanck L.J. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA 100 (2003) 4078-4083
15. Whitworth A.J., Theodore D.A., Greene J.C., Benes H., Wes P.D., and Pallanck L.J. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. Proc Natl Acad Sci USA 102 (2005) 8024-8029
16. Palacino J.J., Sagi D., Goldberg M.S., Krauss S., Motz C., Wacker M., Klose J., and Shen J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279 (2004) 18614-18622
17. Muftuoglu M., Elibol B., Dalmizrak O., Ercan A., Kulaksiz G., Ogus H., Dalkara T., and Ozer N. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov Disord 19 (2004) 544-548
18. ••] were the first to report the consequences of pink1 loss-of-function in vivo and the genetic interaction between pink1 and parkin. Deletion mutants of pink1 in Drosophila showed mitochondrial morphological defects in the male germline and muscle, stress sensitivity and reduced ATP content. The authors also showed unequivocally that Pink1 localizes predominantly to mitochondria in vivo. pink1 mutant phenotypes were rescued by overexpression of parkin, but overexpression of pink1 did not rescue parkin mutant phenotypes. In addition, human PINK1 rescued fly pink1 mutant phenotypes, establishing the functional conservation between human and fly Pink1.
19. ••] were the first to report the consequences of pink1 loss-of-function in vivo and the genetic interaction between pink1 and parkin. The authors demonstrate that pink1 deletion in Drosophila results in mitochondrial morphological defects in the male germline, muscle and dopaminergic neurons, reduced ATP content, reduced mitochondrial DNA and protein content, and mild loss of dopaminergic neurons. The authors also report that pink1 mutant phenotypes can be rescued by overexpression of either the fly Bcl-2 homolog buffy or parkin, whereas overexpression of pink1 does not compensate for parkin loss-of-function.
20. Yang Y., Gehrke S., Imai Y., Huang Z., Ouyang Y., Wang J.W., Yang L., Beal M.F., Vogel H., and Lu B. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci USA 103 (2006) 10793-10798. The authors report that RNAi knockdown of pink1 in Drosophila results in morphological defects in muscle mitochondria, reduced ATP content, mild loss of dopaminergic neurons, and decreased dopamine levels in the head. pink1 knockdown phenotypes were rescued by human PINK1 and PARKIN but not by DJ-1. Moreover, in pink1 knockdown flies, Parkin protein levels were reduced, suggesting a possible mechanism for the pink1-parkin genetic interaction.
21. Wang D., Qian L., Xiong H., Liu J., Neckameyer W.S., Oldham S., Xia K., Wang J., Bodmer R., and Zhang Z. Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila. Proc Natl Acad Sci USA 103 (2006) 13520-13525
22. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., and Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
23. Unoki M., and Nakamura Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20 (2001) 4457-4465
24. Hoepken H.H., Gispert S., Morales B., Wingerter O., Del Turco D., Mulsch A., Nussbaum R.L., Muller K., Drose S., Brandt U., et al. Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol Dis 25 (2007) 401-411
25. Ahlqvist G., Landin S., and Wroblewski R. Ultrastructure of skeletal muscle in patients with Parkinson's disease and upper motor lesions. Lab Invest 32 (1975) 673-679
26. Bindoff L.A., Birch-Machin M.A., Cartlidge N.E., Parker Jr. W.D., and Turnbull D.M. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J Neurol Sci 104 (1991) 203-208
27. Wiedemann F.R., Winkler K., Lins H., Wallesch C.W., and Kunz W.S. Detection of respiratory chain defects in cultivated skin fibroblasts and skeletal muscle of patients with Parkinson's disease. Ann N Y Acad Sci 893 (1999) 426-429
28. Ibanez P., Lesage S., Lohmann E., Thobois S., De Michele G., Borg M., Agid Y., Durr A., and Brice A. Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain 129 (2006) 686-694
29. Yamamoto A., Friedlein A., Imai Y., Takahashi R., Kahle P.J., and Haass C. Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity. J Biol Chem 280 (2005) 3390-3399
30. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 (2004) 1158-1160
31. Gandhi S., Muqit M.M., Stanyer L., Healy D.G., Abou-Sleiman P.M., Hargreaves I., Heales S., Ganguly M., Parsons L., Lees A.J., et al. PINK1 protein in normal human brain and Parkinson's disease. Brain 129 (2006) 1720-1731
32. Silvestri L., Caputo V., Bellacchio E., Atorino L., Dallapiccola B., Valente E.M., and Casari G. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 14 (2005) 3477-3492
33. Beilina A., Van Der Brug M., Ahmad R., Kesavapany S., Miller D.W., Petsko G.A., and Cookson M.R. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc Natl Acad Sci USA 102 (2005) 5703-5708
34. Shimura H., Hattori N., Kubo S., Yoshikawa M., Kitada T., Matsumine H., Asakawa S., Minoshima S., Yamamura Y., Shimizu N., et al. Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol 45 (1999) 668-672
35. Darios F., Corti O., Lucking C.B., Hampe C., Muriel M.P., Abbas N., Gu W.J., Hirsch E.C., Rooney T., Ruberg M., et al. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet 12 (2003) 517-526
36. Kuroda Y., Mitsui T., Kunishige M., Shono M., Akaike M., Azuma H., and Matsumoto T. Parkin enhances mitochondrial biogenesis in proliferating cells. Hum Mol Genet 15 (2006) 883-895. This paper reports the presence of Parkin within mitochondria. Using immunoelectron microscopy, the authors found that the Parkin protein is associated with mitochondrial cristae in a mammalian neuronal cell line under conditions of proliferation. Moreover, Parkin physically interacted with TFAM, and parkin overexpression enhanced transcription and replication of mitochondrial DNA.
37. McBride H.M., Neuspiel M., and Wasiak S. Mitochondria: more than just a powerhouse. Curr Biol 16 (2006) R551-R560
38. Rosen K.M., Veereshwarayya V., Moussa C.E., Fu Q., Goldberg M.S., Schlossmacher M.G., Shen J., and Querfurth H.W. Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells. J Biol Chem 281 (2006) 12809-12816
39. Ved R., Saha S., Westlund B., Perier C., Burnam L., Sluder A., Hoener M., Rodrigues C.M.P., Alfonso A., Steer C., et al. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of α-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J Biol Chem 280 (2005) 42655-42668
40. Kuroda Y., Mitsui T., Kunishige M., and Matsumoto T. Parkin affects mitochondrial function and apoptosis in neuronal and myogenic cells. Biochem Biophys Res Commun 348 (2006) 787-793
41. Chan D.C. Mitochondria: dynamic organelles in disease, aging, and development. Cell 125 (2006) 1241-1252
42. Abeliovich A., and Flint Beal M. Parkinsonism genes: culprits and clues. J Neurochem 99 (2006) 1062-1072
43. Meulener M., Whitworth A.J., Armstrong-Gold C.E., Rizzu P., Heutink P., Wes P.D., Pallanck L.J., and Bonini N.M. Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. Curr Biol 15 (2005) 1572-1577
44. Kinumi T., Kimata J., Taira T., Ariga H., and Niki E. Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. Biochem Biophys Res Commun 317 (2004) 722-728
45. Canet-Aviles R.M., Wilson M.A., Miller D.W., Ahmad R., McLendon C., Bandyopadhyay S., Baptista M.J., Ringe D., Petsko G.A., and Cookson M.R. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA 101 (2004) 9103-9108
46. Meulener M.C., Xu K., Thomson L., Ischiropoulos H., and Bonini N.M. Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging. Proc Natl Acad Sci USA 103 (2006) 12517-12522. The authors demonstrate that mutating a conserved cysteine residue in fly DJ-1 to prevent oxidative modification abrogates the ability of DJ-1 to protect against oxidative insults in Drosophila. Mutation of this same residue to aspartic acid to mimic cysteine modification also attenuates the protective action of DJ-1. The authors further report that cysteine modification of DJ-1 increases with age in flies, mice and humans. In flies, increased modification of DJ-1 correlated with reduced oxidative stress tolerance suggesting that, although cysteine modification is required for the protective effects of DJ-1, excessive cysteine modification might counteract this effect.
47. Zhang L., Shimoji M., Thomas B., Moore D.J., Yu S.W., Marupudi N.I., Torp R., Torgner I.A., Ottersen O.P., Dawson T.M., et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet 14 (2005) 2063-2073
48. Tang B., Xiong H., Sun P., Zhang Y., Wang D., Hu Z., Zhu Z., Ma H., Pan Q., Xia J.H., et al. Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. Hum Mol Genet 15 (2006) 1816-1825
49. Moore D.J., Zhang L., Troncoso J., Lee M.K., Hattori N., Mizuno Y., Dawson T.M., and Dawson V.L. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum Mol Genet 14 (2005) 71-84
50. Martin L.J., Pan Y., Price A.C., Sterling W., Copeland N.G., Jenkins N.A., Price D.L., and Lee M.K. Parkinson's disease α-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 26 (2006) 41-50. This study reports that expressing pathogenic mutant forms of SNCA alone in mice results in the presence of aberrant mitochondria in axons and dendrites of affected neurons, reduced activity of the mitochondrial respiratory chain, and mtDNA damage.
51. Abou-Sleiman P.M., Muqit M.M., and Wood N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 7 (2006) 207-219
52. Fornai F., Schluter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., Lazzeri G., Busceti C.L., Pontarelli F., Battaglia G., et al. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci USA 102 (2005) 3413-3418
53. Betarbet R., Canet-Aviles R.M., Sherer T.B., Mastroberardino P.G., McLendon C., Kim J.H., Lund S., Na H.M., Taylor G., Bence N.F., et al. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis 22 (2006) 404-420
54. Stichel C.C., Zhu X.R., Bader V., Linnartz B., Schmidt S., and Lubbert H. Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage. Hum Mol Genet (2007). http://hmg.oxfordjournals.org/ 10.1093/hmg/ddm083. The authors demonstrate that mitochondria from parkin knockout mice and mice expressing mutant human SNCA exhibit defects in mitochondrial respiration. parkin mutant mice expressing SNCA also displayed age-dependent defects in mitochondrial morphology within dopaminergic neurons. These defects were also seen in mice either mutant for parkin or expressing SNCA more frequently than in wild type mice, but the number of damaged mitochondria only reached statistical significance in mice with both genetic modifications.